Global Radiation Therapy Lung Cancer Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Radiation Therapy Lung Cancer Market Size

• The global radiation therapy for lung cancer market size was valued at USD 7.33 billion in 2025 and is expected to reach USD 16.18 billion by 2033, at a CAGR of 10.41% during the forecast period
• Market growth is primarily driven by the rising incidence of lung cancer globally, increasing adoption of advanced radiation technologies, and growing preference for non-invasive cancer treatment modalities
• In addition, technological advancements such as image-guided and proton therapy systems, along with improved treatment precision and reduced side effects, are significantly supporting market expansion

Radiation Therapy Lung Cancer Market Analysis

• Radiation therapy for lung cancer plays a critical role in both curative and palliative treatment, especially for non-small cell lung cancer (NSCLC), which accounts for the majority of cases globally
• Increasing prevalence of lung cancer due to smoking, air pollution, and occupational exposure is a key factor boosting demand for radiation-based treatment options
• Hospitals and specialized cancer centers dominate the market due to the availability of advanced linear accelerators and skilled oncology professionals
• North America dominated the global radiation therapy for lung cancer market, with the largest market share of 38.7%% in 2025, supported by high healthcare expenditure, strong cancer screening programs, and early adoption of advanced radiation technologies
• Asia-Pacific is expected to witness the fastest growth in the global radiation therapy for lung cancer market due to rising cancer burden, improving healthcare infrastructure, and increasing access to radiotherapy services in countries such as China and India
• External beam radiation therapy (EBRT) dominated the global radiation therapy for lung cancer market with a market share of 7% due to its wide use in treating all major lung cancer stages and strong adoption of advanced systems such as LINAC, IMRT, and IGRT, while brachytherapy and radiopharmaceuticals remain niche segments with limited application

Report Scope and Radiation Therapy Lung Cancer Market Segmentation

Radiation Therapy Lung Cancer Market Trends

“Growing Adoption of Advanced Precision Radiotherapy Technologies”

• A significant and accelerating trend in the global radiation therapy lung cancer market is the growing adoption of advanced precision radiotherapy technologies, particularly image-guided radiation therapy (IGRT), stereotactic body radiation therapy (SBRT), adaptive radiotherapy, and AI-enabled treatment planning systems. These innovations are transforming lung cancer treatment by enabling highly accurate tumor targeting while minimizing radiation exposure to surrounding healthy tissues, thereby improving treatment outcomes and reducing side effects.
• For instance, Varian Medical Systems offers the Ethos adaptive radiotherapy platform, which utilizes artificial intelligence to automatically adapt treatment plans based on daily anatomical changes in patients. Similarly, Elekta has expanded the adoption of its Unity MR-Linac system, which combines magnetic resonance imaging (MRI) with radiation delivery, enabling real-time visualization of lung tumors during treatment
• The integration of artificial intelligence into radiation oncology workflows is enhancing treatment precision and operational efficiency. AI-powered contouring and planning solutions can automatically identify tumor boundaries and critical organs, reducing planning time and improving consistency across treatment centers. In addition, adaptive radiotherapy technologies continuously adjust treatment plans to account for tumor shrinkage, respiratory motion, and anatomical changes throughout the treatment course, ensuring optimal radiation delivery
• The increasing use of SBRT for early-stage non-small cell lung cancer (NSCLC) is further accelerating this trend. SBRT delivers highly concentrated radiation doses in fewer treatment sessions, offering outcomes comparable to surgery for many medically inoperable patients. The combination of advanced imaging, motion management, and AI-driven planning is enabling clinicians to safely administer higher radiation doses with greater confidence
• This shift toward more personalized, data-driven, and precision-focused radiotherapy is fundamentally reshaping lung cancer care worldwide. Consequently, leading companies such as Siemens Healthineers, Varian Medical Systems, and Elekta are investing heavily in AI-enabled treatment planning, adaptive radiotherapy platforms, and advanced imaging-guided radiation systems to enhance clinical outcomes and support the growing demand for precision lung cancer treatment

Radiation Therapy Lung Cancer Market Dynamics

Driver

“Rising Lung Cancer Incidence and Aging Population”

• The global rise in lung cancer cases, driven by smoking prevalence, air pollution, occupational hazards, and lifestyle factors, is significantly increasing the demand for radiation therapy solutions across all stages of the disease
• Aging populations are more vulnerable to cancer due to weakened immunity and longer exposure to risk factors, leading to higher treatment volumes and sustained demand for advanced oncology care
• Improved screening programs and early diagnosis rates are also contributing to a growing number of patients eligible for radiation therapy, further supporting market expansion

Restraint/Challenge

“High Cost of Advanced Radiation Systems”

• Advanced radiation therapy systems such as proton therapy, MRI-guided radiotherapy, and high-end linear accelerators require substantial capital investment, making them less accessible for smaller healthcare facilities
• High installation, maintenance, and operational costs, along with the need for specialized infrastructure and trained professionals, significantly increase the overall treatment cost burden
• These financial constraints limit adoption in developing and price-sensitive regions, restricting the widespread deployment of next-generation radiation therapy technologies

Radiation Therapy Lung Cancer Market Scope

The market is segmented on the basis of type of radiation therapy, technology, indication, and end user.

• By Type of Radiation Therapy

On the basis of type of radiation therapy, the global radiation therapy for lung cancer market is segmented into External Beam Radiation Therapy (EBRT), Internal Radiation Therapy (Brachytherapy), and Systemic Radiation Therapy (Radiopharmaceuticals). The External Beam Radiation Therapy (EBRT) segment dominated the market with the largest revenue share of 72.7% in 2025, driven by its widespread adoption as the standard treatment modality for lung cancer across early-stage, locally advanced, and palliative care settings. EBRT is highly preferred due to its precision, non-invasive nature, and compatibility with advanced systems such as IMRT, IGRT, and SBRT, which enhance treatment accuracy while minimizing damage to surrounding healthy tissues. Its broad availability across hospitals and cancer treatment centers further strengthens its market dominance.

The Systemic Radiation Therapy (Radiopharmaceuticals) segment is expected to witness fastest growth during the forecast period, driven by increasing research in targeted radionuclide therapies for advanced and metastatic lung cancer cases. Growing interest in precision oncology and personalized treatment approaches is further supporting the development and adoption of systemic radiation solutions.

• By Technology

On the basis of technology, the global radiation therapy for lung cancer market is segmented into Linear Accelerators (LINAC-based systems), Stereotactic Systems (SBRT/SRS), Image-Guided Radiation Therapy (IGRT), Intensity-Modulated Radiation Therapy (IMRT), Proton Therapy Systems, and MRI-guided Radiation Therapy. The Linear Accelerators (LINAC-based systems) segment dominated the market in 2025 due to their widespread installation across healthcare facilities and their role as the backbone of external beam radiation therapy. LINAC systems are widely used for their reliability, cost-effectiveness, and ability to deliver precise radiation doses.

The Stereotactic Systems (SBRT/SRS) segment is expected to witness fastest growth in the market during the forecast period, driven by increasing adoption for early-stage lung cancer treatment due to its ability to deliver high-dose radiation in fewer sessions with improved tumor targeting.

• By Indication

On the basis of indication, the global radiation therapy for lung cancer market is segmented into Early-stage non-small cell lung cancer (NSCLC), Locally advanced lung cancer, Metastatic lung cancer, and Palliative care cases (pain and symptom control). The Locally advanced lung cancer segment dominated the market in 2025, as radiation therapy is a key treatment modality often used in combination with chemotherapy for disease control and survival improvement.

The Early-stage NSCLC segment is expected to grow with the fastest CAGR during the forecast period due to rising adoption of stereotactic techniques such as SBRT, which offer curative outcomes with minimal invasiveness.

• By End User

On the basis of end user, the global radiation therapy for lung cancer market is segmented into Hospitals, Cancer Treatment Centers / Oncology Clinics, Academic & Research Cancer Institutes, and Ambulatory Radiotherapy Centers. The Hospitals segment dominated the market in 2025 due to high patient inflow, availability of advanced radiation therapy systems, and comprehensive oncology departments. Hospitals remain the primary point of care for lung cancer diagnosis and treatment.

The Cancer Treatment Centers / Oncology Clinics segment is expected to witness the fastest growth during the forecast period, driven by increasing establishment of specialized cancer care facilities offering advanced and targeted radiation therapies with improved patient outcomes and shorter treatment cycles.

Radiation Therapy Lung Cancer Market Regional Analysis

• North America dominated the global radiation therapy for lung cancer market, accounting for 38.7% share in 2025, due to advanced healthcare infrastructure, high cancer prevalence, and strong adoption of cutting-edge technologies such as IMRT, SBRT, and proton therapy. The U.S. dominates regional demand with strong reimbursement frameworks and early technology adoption
• High prevalence of lung cancer cases and well-established national cancer screening programs are driving consistent demand for advanced radiation therapy services across the region
• Strong presence of leading medical device manufacturers and continuous technological innovation are accelerating the deployment of next-generation radiotherapy systems in oncology centers

U.S. Radiation Therapy Lung Cancer Market Insight

The U.S. radiation therapy for lung cancer market is highly advanced and holds the largest share in North America, driven by a high prevalence of lung cancer, strong healthcare infrastructure, and early adoption of advanced technologies such as IMRT, IGRT, SBRT, and proton therapy. The country benefits from robust reimbursement policies, extensive cancer screening programs, and significant investments in oncology research, which support widespread access to modern radiation treatment. In addition, the presence of leading medical device manufacturers and continuous technological innovation further strengthens market growth in the U.S.

Europe Radiation Therapy Lung Cancer Market Insight

The Europe radiation therapy for lung cancer market is witnessing steady growth, supported by strong public healthcare systems, increasing lung cancer incidence, and widespread adoption of advanced radiotherapy technologies such as IMRT, IGRT, and SBRT. The region benefits from well-established cancer care infrastructure and strong government initiatives focused on early diagnosis and effective cancer treatment. In addition, rising investments in precision oncology and the presence of leading medical technology companies are further driving the adoption of advanced radiation therapy solutions across major European countries such as Germany, the U.K., and France.

U.K. Radiation Therapy Lung Cancer Market Insight

The U.K. radiation therapy for lung cancer market is growing steadily, supported by a strong public healthcare system through the NHS, increasing lung cancer incidence, and rising adoption of advanced radiotherapy techniques such as IMRT, IGRT, and SBRT. Government-led cancer control programs and early screening initiatives are improving diagnosis rates and expanding treatment access. In addition, growing investment in modern oncology infrastructure and increasing focus on precision-based cancer care are further supporting the adoption of advanced radiation therapy solutions across the country.

Germany Radiation Therapy Lung Cancer Market Insight

The Germany radiation therapy for lung cancer market is expanding steadily, driven by a high burden of lung cancer, strong healthcare infrastructure, and advanced oncology treatment capabilities. The country is a key adopter of precision radiation technologies such as IMRT, IGRT, and SBRT, supported by its well-established network of cancer centers and hospitals. In addition, strong government support for cancer research, high investment in medical technology, and the presence of leading radiation therapy equipment manufacturers are further strengthening market growth in Germany.

Asia-Pacific Radiation Therapy for Lung Cancer Market Insight

The Asia-Pacific radiation therapy for lung cancer market is witnessing rapid growth, driven by a rising incidence of lung cancer, expanding healthcare infrastructure, and increasing adoption of advanced radiotherapy technologies such as IMRT, IGRT, and SBRT. Countries such as China, India, and Japan are investing heavily in modern oncology facilities and improving access to cancer treatment services. In addition, growing government initiatives for cancer awareness, increasing healthcare expenditure, and availability of cost-effective treatment options are further accelerating market expansion across the region, making Asia-Pacific the fastest-growing market globally.

Japan Radiation Therapy for Lung Cancer Market Insight

The Japan radiation therapy for lung cancer market is growing steadily, supported by a high aging population, increasing lung cancer incidence, and strong adoption of advanced radiation technologies such as IMRT, IGRT, SBRT, and proton therapy. The country benefits from a highly developed healthcare system, strong focus on precision medicine, and extensive use of technologically advanced oncology equipment. In addition, government support for cancer research, widespread availability of specialized cancer centers, and continuous innovation in radiotherapy systems are further driving market growth in Japan.

India Radiation Therapy Lung Cancer Market Insight

The India radiation therapy for lung cancer market is witnessing strong growth, driven by a rising burden of lung cancer, rapid urbanization, and increasing exposure to risk factors such as air pollution and tobacco use. Expanding healthcare infrastructure and growing investments in oncology centers are improving access to advanced radiation therapies such as IMRT, IGRT, and SBRT. In addition, government initiatives supporting cancer awareness, early diagnosis, and affordable treatment options, along with the increasing presence of private cancer care providers, are further accelerating market growth across the country.

Radiation Therapy Lung Cancer Market Share

The Radiation therapy for lung cancer industry is primarily led by well-established companies, including:

• Siemens Healthineers AG (Germany)
• Elekta AB (Sweden)
• Accuray Incorporated (U.S.)
• IBA Worldwide (Belgium)
• Mevion Medical Systems (U.S.)
• ViewRay Technologies, Inc. (U.S.)
• RaySearch Laboratories AB (Sweden)
• Brainlab AG (Germany)
• Hitachi, Ltd. (Japan)
• Mitsubishi Electric Corporation (Japan)
• Canon Medical Systems Corporation (Japan)
• Sumitomo Heavy Industries, Ltd. (Japan)
• RefleXion (U.S.)
• Panacea Medical Technologies Pvt. Ltd. (India)
• Nordion (Canada) Inc. (Canada)

What are The Recent Developments in Global Radiation Therapy for Lung Cancer Market?

• In May 2025, Siemens Healthineers (Varian Medical Systems) introduced enhanced AI-driven adaptive radiotherapy solutions integrated into its Ethos platform, aimed at improving real-time tumor tracking and treatment precision for lung cancer patients, strengthening its leadership in advanced LINAC-based systems.
• In May 2024, Elekta AB launched its AI-powered adaptive CT-Linac “Evo,” designed to improve imaging-guided radiotherapy workflows and enable more precise treatment delivery for complex lung cancer cases, enhancing clinical efficiency and patient outcomes.
• In December 2024, Varian (a Siemens Healthineers company) received FDA clearance for its latest RapidArc Dynamic radiotherapy technology, enabling faster and more precise dose delivery in external beam radiation therapy for oncology applications, including lung cancer treatment.
• In August 2024, Accuray Incorporated obtained CE Mark approval for its next-generation helical radiation delivery system, expanding access to advanced stereotactic radiotherapy solutions used in lung cancer treatment across European markets.

SKU-76080